资源类型：
期刊
WOS体系：
Letter
Pubmed体系：
Letter;Multicenter Study;Randomized Controlled Trial;Research Support, Non-U.S. Gov't
收录情况：
◇ SCIE
◇ CSCD-C
◇ 卓越：领军期刊
文章类型：
书信
机构：
[1]Department ofImmunologyandBiotherapy,KeyLaboratoryof Cancer ImmunologyandBiotherapy,KeyLaboratoryofCancer Prevention andTherapy,Tianjin’s ClinicalResearchCenterforCancer, Tianjin MedicalUniversityCancerInstituteandHospital,Tianjin 300060, China
[2]Department ofImmunotherapy,Affiliated Cancer Hospital ofZhengzhouUniversity&HenanCancerHospital, Zhengzhou 450008Henan,China
河南省肿瘤医院
[3]Department ofTumorBiological Treatment, ThirdAffiliated HospitalofSoochowUniversity, Changzhou 213003Jiangsu,China
[4]Department ofOncology, Shanxi BethuneHospital,Taiyuan030032Shanxi,China
[5]Cancer Biotherapy Center,ThirdAffiliated HospitalofKunmingMedical University (TumorHospitalofYunnanProvince),Kunming650118 Yunnan, China
[6]Cancer Center,FirstHospitalofJilinUniversity, Changchun 130021Jilin,China
[7]Laboratory ofImmuno-Oncology, Fujian Cancer Hospital &Fujian Medical University Cancer Hospital, Fuzhou 350014Fujian,China
[8]Department of Immuno- Oncology, Fourth Hospital of Hebei Medical University,Shijiazhuang 050011 Hebei,China
河北医科大学第四医院
肿瘤免疫科
临床科室
ISSN：
2095-9907
基金：
This work was supported by the National Key Technologies R&D Program of China grant Awards No. 2015BAI12B12 (to X.R.) and 2018YFC1313400 (to J.X.), by the National Natural Science Foundation of China grants Awards No. 81572913 and 81872487 (to L.L.).
被引次数：
14
WOS：
WOS:000583299800004
PubmedID：
33077722
中科院分区：
出版当年[2020]版：
大类
|
1 区
医学
小类
|
1 区
生化与分子生物学
1 区
细胞生物学
最新[2025]版：
大类
|
1 区
医学
小类
|
1 区
生化与分子生物学
1 区
细胞生物学
JCR分区：
出版当年[2020]版：
Q1
BIOCHEMISTRY & MOLECULAR BIOLOGY
Q1
CELL BIOLOGY
最新[2023]版：
Q1
BIOCHEMISTRY & MOLECULAR BIOLOGY
Q1
CELL BIOLOGY
影响因子：
40.8
最新[2023版]
40.6
最新五年平均
18.187
出版当年[2020版]
21.177
出版当年五年平均
13.493
出版前一年[2019版]
38.12
出版后一年[2021版]
第一作者：
Liang Liu
第一作者机构：
[1]Department ofImmunologyandBiotherapy,KeyLaboratoryof Cancer ImmunologyandBiotherapy,KeyLaboratoryofCancer Prevention andTherapy,Tianjin’s ClinicalResearchCenterforCancer, Tianjin MedicalUniversityCancerInstituteandHospital,Tianjin 300060, China
通讯作者：
Xinwei Zhang;Xiubao Ren
推荐引用方式(GB/T 7714)：
Liang Liu,Quanli Gao,Jingting Jiang,et al.Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357(Open Access)[J].SIGNAL TRANSDUCTION AND TARGETED THERAPY.2020,5(1):doi:10.1038/s41392-020-00337-x.
APA：
Liang Liu,Quanli Gao,Jingting Jiang,Junping Zhang,Xin Song...&Xiubao Ren.(2020).Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357(Open Access).SIGNAL TRANSDUCTION AND TARGETED THERAPY,5,(1)
MLA：
Liang Liu,et al."Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357(Open Access)".SIGNAL TRANSDUCTION AND TARGETED THERAPY 5..1(2020)
医学